S.Bhagatetal./InternationalJournalofSurgery11(2013)209e217
211
3.Evidencesynthesis
SearchonCochraneLibrarydatabaseusingkeyword‘Serratio-peptidase’revealed16resultsamongwhich8wereRCTsrelatedtoef cacyofSerratiopeptidase.Arepeatedsearchonthesamedata-baseusingkeyword‘Serrapeptase’revealed9resultsamongwhich6wereRCTs.Therefore,atotalof11RCTswereincludedinourreviewexcludingthosewhichwereduplicatedandwherefulltextwasnotavailable.
PubMedsearchusingkeywords‘Serratiopeptidase’or‘Serra-peptase’revealed74resultswhichshowed16clinicaltrialsoutofwhich9wereRCTsrelatedtoef cacyofSerratiopeptidase.Thus,atotalof14RCTswereincludedinourreview.Onlythosestudieswereincludedwhichwerepublishedandwherefulltextwasavailableexcludingthosewithduplicateresults.Variouspublishedstudieshavere ectedtheuseofSerratiopeptidaseforitsanti-in ammatory,anti-edemicandanalgesiceffects.Someanecdotalstudiessuggestittopossessanti-atheroscleroticeffectsalso.
Therewere6clinicalstudies(Table1)supportingtheanti-in ammatoryeffectsofSerratiopeptidase.Butamongtheseclini-caltrialsthedoseanddurationoftherapywasnotspeci edin2ofthesestudiesandwerehavingsmallsamplesize,3wereplacebo-controlledtrials,while1studywithactivecomparatorSeaproseS(SAP)hadshownSeaproseStobebetterthanSerratiopeptidase.Therewere3studiesindentalpatientstoseethepostoperativeanti-in ammatoryeffectsofSerratiopeptidase(Table1).
InonestudybyKhateebetal.,24SerratiopeptidaseþParacetamolcombinationwascomparedtoPlaceboþParacetamolinpatientsaftersurgicalremovalofimpactedthirdmolars.ItwasconcludedthatSerratiopeptidaseþparacetamolgroupshowedsigni cantreductioninextentofcheekswellingandpain,buttherewasnodifferenceinmeanmaximalinterincisaldistancebetweenthetwogroups.SimilarstudybyChopraetal.25comparingSerratiopeptidasewithibuprofen/betamethasone/paracetamol/placeboshowedser-ratiopeptidasegrouptohavelessmeanpainscoresandswellingascomparedtoplacebobutthedifferencewasnotstatisticallysigni -cant.Moreover,serratiopeptidasewasnotsuperiorwhencomparedtoibuprofenandbetamethasone.ThethirdstudybySurachaietal.26inpatientswithpostoperativeswellingafterremovalofimpactedmolarsdidnotshowanysigni cantdifferenceindegreeoffacialswellingintheSerratiopeptidaseandnomedicationgroups.Itwasatrialwithsmallsamplesizeandstudydesignnotmentioned.
Further5studiesindifferentotorhinolaryngologypathol-ogies1,16e20havetriedtoexplorethemucolyticpropertiesofser-ratiopeptidase.Twowereplacebo-controlledtrials,amongwhichonestudy1showedSerratiopeptidasereducedthesymptomsofseverityofpain,amountandpurulenceofsecretionsbutinthesecondstudy16outcomeswereunclear.Anotherprospective,openlabelstudy19showedSerratiopeptidasetoreducetheviscositybutnottheelasticityofsecretionsinpatientsofchronicsinusitis.Similarly,onestudy20inchronicairwaydiseasepatientscomparedSerratiopeptidasewithnon-treatmentgroupandconcludedittoreducesputumviscosity,elasticityandneutrophilcount.Therewasonlyonestudy17inchronicrespiratorydiseasepatientswithdif- cultyinexpectoration,whereSerratiopeptidasewascomparedwithanactivecomparatorSeaproseSandthisstudyshowedSeaproseStobebetterthanSerratiopeptidaseinrelievingdif cultyinexpectorationandspeci csymptoms.
Insomestudies21e23theroleofSerratiopeptidaseinincreasingtheeffectiveconcentrationofantimicrobialsindifferenttissueswasstudied.TheseshowedthatSerratiopeptidaseincreasedtheconcentrationofantimicrobialsintissues.Butamongthesestudies,onewasprospectiveopenlabeltrial.21Oneofthestudies22didnotmentionthedurationoftherapyandotherwasarandomised,openlabeltrialinwhichSerratiopeptidaseþcefotiamwasadministered
forprophylaxisbeforesurgery,butagaindurationoftreatmentwasnotgiven.
Bandolier27onlineedition(retrievedon1/5/2011)showedare-view“Serratiopeptidase- ndingtheevidence”.Thisreviewcon-cludedthattherewerenotrialsofSerratiopeptidasefortreatmentofbackpain,neithertherewereanytrialsforitsuseinheartattackandstroke.Amongthe9RCTsincludedinthisreviewwhichweregen-erallysaidtobeofpoormethodologicalquality, vestudiesweredescribedasdouble-blind:onewascompletelyun-interpretable,threemethodologicallyweakstudieswerepositiveandonetrialofapparenthighqualitywasnegative.
3.1.Evidencefromclinicalandpreclinicalstudies
Atotalof24studiesonef cacyofSerratiopeptidasewereincludedwhichmettheinclusioncriteria.Amongthese18wereclinicaland6werepreclinicalstudies(Tables1and2).3.2.Clinicalevidence
SerratiopeptidasehasbeenusedinSurgery(Traumaticandpostoperativein ammation,4,14venousin ammatorydisease,15cystitis,epididymitis34),Orthopaedics(Traumaticswellingaftersportsinjury,4carpaltunnelsyndrome,7osteoarticularinfectiontoincreaseantibioticconcentrationatinfectionsite21),Otolaryngology(Sinusitis,rhinitis,laryngitis,bronchitis,inadequateexpectorationofsputuminbronchialasthma1,19,20),Gynaecology(Engorgementofbreasts5,35),Dentistry(Anti-in ammatoryandtoincreaseantibioticconcentrationatsiteofinfectioninperiodontitis,36pericoronitisofwisdomtooth25).
TheevidencefromclinicalstudieshasbeengradedaccordingtothechecklistgivenbytheScottishIntercollegiateGuidelinesNet-work(SIGN).12Thegradingshowedthatthestudiessupportingtheanti-in ammatoryandanalgesicroleofSerratiopeptidasearegenerallyofpoormethodology.Firstlythenumberofstudiesareonlyfew.Secondly,thestudieswhicharethere,eitherhaveasmallsamplesize(notmorethan150patientspergroupinanyofthestudies)orareofshortduration.Moreover,thestudiesaremostlyplacebo-controlledtrialsandlackanactivecomparator.Alsotheeligibilitycriteriaandoutcomevariablesarenotwellde nedand nallythestatisticalmethodsusedforanalysingthesigni cancelevelhavenotbeenexplained(Table1).3.3.Studiesinanimals
Thestudiesinanimalsareveryfew.Thesehaveonlydemon-stratedtheanti-in ammatoryeffectsofSerratiopeptidase.Nospeci cmodelhasbeenusedinanyofthesestudiestoscreenfortheanalgesicandanti-atheroscleroticeffectsofthisenzymeinparticular(Table2).In3animalstudies28e30Serratiopeptidasewasshowntoincreasetheantimicrobialconcentrationatthesiteofinfection.Whilein2studies32,33usinganti-in ammatoryanimalmodelsitwasshownthatSerratiopeptidasedemonstratedsigni -cantanti-in ammatoryactivitywhencomparedtochymotrypsin,trypsin,aspirinanddiclofenac.Inanotherstudy,31whereSerra-tiopeptidasewascomparedtoactivecomparatorseaprose.Bothenzymesshowedreductioninviscosityofsputum,butthedurationoftherapywasnotmentioned.4.Source
Serratiopeptidaseisderivedfromnon-pathogenicenter-obacteriabelongingtogenusSerratiaspeciesE-15.Thismicro-organismwasoriginallyisolatedduringlate1960sfromtheintestinesofsilkwormBombyxmoriwhichisitsnaturalhabitat.
evidence in making decisions about the care of individual?patients.(Sackett,?DL)? ? A systematic review is a comprehensive study of A?systematic?review?...
The_Level_of_Evidence_Pyramid__Indicating_Levels.47_临床医学_医药卫生_专业...a systematic review of these studies Case-control study; or any of the ...
-aventis Second edition Evidence-based medicine What is a systematic review?...existing agendas have failed to address a clinical problem G Increasingly ...
(Lepidium meyenii) for treatment of menopausal symptoms A systematic review_... a qualitative review and opted for a synthesis of the best evidence. ...
A Systematic Review of Xuezhikang, for Coronary Heart Disease Complicated by... Hindawi Publishing Corporation Evidence-Based Complementary and Alternative ...
of Findings table for a Cochrane systematic review_经济学_高等教育_教育专区...GRADE of the quality of evidence (last column and footnotes of the SoF)...
provide stronger evidence than a ‘higher level’ study – say a systematic review of few studies leading to an inconclusive result (see Background ...
we performed a systematic review and meta-analysis of the current evidence for the association between ALA exposure, including studies of dietary ALA and ...
systematic reniew and meta-analysis of the effects of high protein oral ...The systematic review and meta-analysis provides evidence that high protein ...
It may provide bene?ts and clinical evidence for both patients and clinicians. Although a related systematic review has been published by Hao and ...
热门文档